Trimethobenzamide
Aminoalkyl Ethers
- Drug class
- Aminoalkyl Ethers
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 1
Overview
Plain-language summary, compiled from the cited regulatory records
Trimethobenzamide is an active pharmaceutical ingredient classified as an aminoalkyl ether [1]. It is approved for use in adults to manage specific types of nausea and vomiting [1].
Specifically, trimethobenzamide is indicated for the treatment of nausea and vomiting that occurs after surgery [1]. It is also used for nausea associated with gastroenteritis, which is inflammation of the stomach and intestines [1].
Trimethobenzamide hydrochloride capsules are not recommended for use in pediatric patients. This is due to potential risks, including extrapyramidal signs and symptoms, other serious central nervous system effects, and the possibility of worsening the underlying disease in children with Reye's syndrome [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | April 4, 2024 |
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Trimethobenzamide hydrochloride capsules is indicated in adults for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
Limitation of Use:
Trimethobenzamide hydrochloride capsules is not recommended for use in pediatric patients due to the risk of extrapyramidal signs and symptoms and other serious central nervous system (CNS) effects, and the risk of exacerbation of the underlying disease in pediatric patients with Reye's syndrome or other hepatic impairment.
Trimethobenzamide hydrochloride capsules are an antiemetic indicated in adults for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. ( 1 ) Limitation of Use: • Trimethobenzamide hydrochloride capsules are not recommended for use in pediatric patients due to the risk of extrapyramidal signs and symptoms and other serious central nervous system (CNS) effects and the risk of exacerbation of the underlying disease in pediatric patients with Reye's syndrome or other hepatic impairment.
Drug interactions
Known interactions involving Trimethobenzamide. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 00ba5395-1455-4e… · revised April 4, 2024 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.